Murali Janakiram is a Hematology physician affiliated with City Of Hope National Medical Center. OpenAlex indexes 278 publications with 5,340 citations (h-index 33); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 Duarte Rd
Duarte, CA 910103012
Telephone
626-256-4673Provider last certified this registry record 9 Aug 2021.
Clinical trials
- Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Sponsor: City of Hope Medical Center
- Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML
Sponsor: Masonic Cancer Center, University of Minnesota
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20252 payments$16,410openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20253 payments
- Janssen Biotech, Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
73.8%Thalidomide Analog61.4%Revlimid43%Lenalidomide30%Pomalyst27%Part D<11 patientsBCL-2 Inhibitor12.4%Venclexta100%Part D<11 patientsDermatology
26.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor26.2%Acyclovir100%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
2025 - Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy
Biology of Blood and Marrow Transplantation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Dana Dominguez
City Of Hope National Medical Center
Swetha Thiruvengadam, MD
City Of Hope National Medical Center
Yuman Fong, MD
City Of Hope National Medical Center
Ravi Salgia, MD, PhD
City Of Hope National Medical Center
Joseph Antin, MD
Boston University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”